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Spicy science: David Julius and the discovery of temperature-sensitive
TRP channels
Diana M Bautista*
Department of Molecular & Cell Biology and Helen Wills Neuroscience Institute; University of California Berkeley; Berkeley, CA USA
This invited biographical review cov-ers the career of Dr. David Julius
and his discovery of thermosensitive
TRP channels. Dr. Julius is currently the
Morris Herzstein Chair in Molecular
Biology and Medicine and Professor and
Chair of Physiology at the University
of California, San Francisco Medical
School. He is a member of the National
Academy of Sciences and has received
many distinguished awards for his land-
mark discoveries of the molecular basis of
pain and thermosensation.
Introduction
The ability to perceive changes in envi-
ronmental temperature is essential for
survival of all organisms. In humans, ther-
mosensation is critical for homeostatic
maintenance of core body temperature
and also for appropriate behavioral
responses to environmental temperature,
such as wearing a coat outside when its
snowing, using a pot holder to grab a red-
hot frying pan, or wearing gloves to han-
dle dry-ice in the laboratory. The quest to
understand thermosensation and pain
spans millennia. Indeed, artwork depict-
ing the use of opium as an analgesic dates
back to 5,000 BC.1 The Greek physician
Galen proposed that sensations, including
pain, were mediated by nerves connecting
the organs to the brain.1 In 1664, Des-
cartes supported Galen’s view on sensory
experiences and expanded further to pro-
vide the first description of how a stimu-
lus, such as noxious heat, might trigger
sensations. An illustration in the Treatise
of Man (Descartes, 1664) depicts how
particles from a hot flame tug on nerve
tubules that connect the skin to spinal
cord and brain, subsequently opening
pores in the brain that trigger pain sensa-
tions and protective motor reflexes.
We now know that changes in environ-
mental temperature in mammals are
detected by primary afferent somatosen-
sory neurons. These neurons have cell
bodies in the dorsal root ganglia (DRG)
for the body and the trigeminal ganglia
for the face/head, and have a pseudo-uni-
polar axon that innervates peripheral tar-
get organs (e.g., skin) and the dorsal
spinal cord. Nociceptors are a specialized
subset of primary afferent neurons that
mediate responses to noxious thermal,
mechanical and/or chemical stimuli.
Nociceptors are activated when tempera-
tures reach levels that are capable of
causing tissue damage; heat-sensitive
nociceptors are activated by temperatures
that exceed 43C, while cold-sensitive
nociceptors are activated by temperatures
that fall below 15C. Such neurons dis-
play little activity at normal body temper-
ature but display robust action potential
firing in response to noxious thermal stim-
uli that in turn activates central neurons to
trigger protective reflexes and irritating or
painful sensations.
A number of studies suggested that
changes in environmental temperature
triggered the opening of temperature-sen-
sitive ion channels in primary afferent
nerve endings. Heat-activated ionic cur-
rents were measured in cultured rodent
primary afferents.2,3 Studies on capsaicin,
the pungent compound in chili peppers
that triggers the psychophysical sensation
of heat, also supported the channel
hypothesis. Capsaicin depolarized heat-
sensitive sensory neurons4 to trigger excit-
ability and electrophysiological experi-
ments on cultured neurons revealed the
activation of non-selective currents.5,6
Likewise, cold-activated currents and cal-
cium signals were also observed in cul-
tured neurons.7,8 However, other
mechanisms were proposed for tempera-
ture-evoked excitability, ranging from a
general perturbation of membrane proper-
ties to the activation or inhibition of a
variety of voltage-gated channels or other
conductances. Thus, it was not clear
whether bona fide temperature-sensitive
ion channels even existed.
In 1997, David Julius, Michael
Caterina, and colleagues used expression
cloning to identify TRPV1, a capsaicin-
and heat-activated ion channel.9 This
non-selective channel was activated by
heat with a threshold of 43C, similar to
the threshold for action potential firing in
sensory neurons and for noxious heat sen-
sations in psychophysical experiments.
Analyses of TRPV1-deficient animals
have revealed a key role for TRPV1 in
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both acute heat detection and thermal
hypersensitivity.10 Thus, TRPV1 became
of great interest as a drug target for treat-
ing pain and inflammation.
TRPV1 was the first of many thermo-
sensitive TRP channels to be identified by
the Julius lab, and many other labs.
Indeed, David Julius has gone on to iden-
tify the cold- and menthol-activated ion
channel, TRPM8,11 and the wasabi recep-
tor, TRPA1,12 both of which play key
roles in acute and inflammatory pain.
Most recently, Drs. Julius and Yifan
Cheng and colleagues generated high-res-
olution structures of the TRPV113,14 and
TRPA115 ion channels, defining regions
that are conserved among TRP channels,
as well as novel domains that give each
channel their unique functions and roles
in pain and inflammation. Importantly,
these structures serve as a much-needed
roadmap for the design of novel drugs to
treat pain, itch and other inflammatory
disorders linked to these channels.
Dr. Julius’ many landmark discoveries
have been discussed at length in a number
of excellent, comprehensive reviews to
which I refer the reader.16-18 Thus, what
follows below is an excerpt of an interview
with Dr. Julius where we discussed his dis-
covery of TRPV1 and other TRP chan-
nels. I was fortunate to have been a
postdoctoral fellow with David and can
say that he was, and continues to be, an
amazing mentor and role model. Indeed,
Michael Caterina (Fig. 1), another former
post-doctoral fellow of Dr. Julius, insists
that, “Working with David was nothing
short of awesome. As a scientist, David
has a ‘sixth sense’ about what will consti-
tute an interesting project and the best
way to make that project come to fruition.
Time after time, he finds a way to blow a
field wide-open by cleverly and cleanly
solving a longstanding problem in that
field. As a mentor, David was incredibly
supportive, in both good times and bad.
Before we cloned TRPV1, I had been
working on another project that was going
nowhere. Even in the darkest days of that
project, however, David provided immea-
surable encouragement, patience and use-
ful suggestions. When we began to realize
that the TRPV1 project was going to be
successful, David used that same enthusi-
asm and energy to deftly lead me and the
rest of our team down the most efficient
path to completing our work. That meant
not only providing oversight, but also roll-
ing up his sleeves and picking thousands
of bacterial colonies late into the evening.
Writing with David was also a joy. We
would sit in his corner office overlooking
the Pacific Ocean and bounce ideas back
and forth for the next line of a paper.
Those sessions provided a great opportu-
nity to learn more broadly about David’s
philosophy of science and life. He is truly
one of a kind.” Everyone I know who has
had the pleasure to work with David
shares these sentiments. His trainees also
appreciate all the hands-on help David
would provide in the lab; getting his hands
dirty at the bench and doing some molec-
ular biology, as evident in the photos
below (Fig 2–3). This interview also
includes details of David’s early career in
science, the events that led a yeast geneti-
cist to neuroscience and some words of
wisdom to others in the field.
Interview recorded February
2015, Department of Physiology,
UCSF
Diana: Tell me about your early career
path and how you became interested in
science.
David: Neither of my parents are scien-
tists. But I became interested in science
because I had a great physics teacher in
high school, Irv Isaacson. He was really
fun, and he made us think about a lot of
stuff. He was fantastic.
I decided to go to MIT even though I
didn’t know much about it. Someone sug-
gested I should I apply there if I was inter-
ested in science. You know, I was so na€ıve,
so I went. I thought I’d be a physician,
because at the time that’s what I thought
about science, that I’d be a medical doc-
tor. Biology was a very small major at the
time I was at MIT. Most people were
studying engineering or physics. There
were a few biology students and about
95% of them were pre-medical. But at
some point that didn’t interest me and I
decided to start working in a lab.
Diana: Tell me about your undergrad-
uate research experience with Alex Rich.
David: I went to Alex’s lab and started
working on tRNA amino acylation and
protein synthesis and my research interests
grew. Alex’s lab was kind of a wild place,
it was just chaos! But I learned a lot there.
People were working on different things
and there was a whole wing of people who
were crystallographers doing tRNA struc-
ture. I met some fascinating people there,
like Ned Zieman who is now considered
one of the fathers of nano-technology, and
Jeremy Nathans. Of course Jeremy was
always precocious and he had this beauti-
ful Nature paper looking at the structure
of DNA with an intercalator.19
I started to appreciate the idea that you
could put together models from doing
Figure 1. David Julius (left) with Michael Caterina (right, former postdoc; now Professor, Johns Hop-
kins School of Medicine) at an awards ceremony in 2014. Reproduced by permission of Michael J
Caterina, MD, PhD, Johns Hopkins School of Medicine.
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experiments that seemed kind of arcane;
that you can take this data and put it
together into a physical idea of what was
happening in the test tube. It fascinated
me that you could start thinking about
things in pictures even though you’re
really doing all these kind of complicated
manipulations and reading them out just
based on say counts coming out of the
scintillation counter. And mostly I liked
doing something where I could do some-
thing physical as well as intellectual and
not just sit around reading and writing. I
liked tinkering and I found that I was
really good at that kind of work.
Diana: Tell me about graduate school
at Berkeley
David: When I went to Berkeley, com-
ing from MIT, I wanted to do something
more molecular. I decided I wanted to
stay in some sort of microorganisms sys-
tem and do something related to develop-
ment. I had talked to Jeremy Thorner. I
heard he wasn’t taking any students so I
never really asked him about joining his
lab. But luckily he asked me “how come
you haven’t talked to me about coming to
my lab?” and I said, “I heard you’re full.”
And he said “there’s always room for a
good person.” At the time, I was in the
Biochemistry Department and he was in
Microbiology. The departments were sep-
arate and I was told that I would have to
take my qualifying exam again if I joined
Jeremy’s lab. So Randy (Schekman)
agreed to be my Biochemistry co-sponsor
even though he didn’t have room in his
lab, and then I ended up doing a joint
project between the 2 of them. Working
on a factor and peptide secretion and
processing was a happy accident. It turned
into a great project and I really learned to
love that area. I noticed at the time, some
people in yeast were geneticists and some
were biochemists and there were very few
people who did both. But Randy and
Jeremy were trained as biochemists in pla-
ces where genetics was also emphasized
and so they combined both. I think that’s
what made their lab so powerful and that
was a big lesson for me.
Diana: So, how did you end up in the
Axel Lab and begin your exploration of
neuroscience?
David: Well, 2 things. About that
time, Richard had published a paper that
was on the cover of Cell, with Sheller and
Kandel, about all these egg-laying hor-
mones in Aplysia. They had these beauti-
ful pictures of the Mag cells, which make
egg-laying hormones, and it’s basically a
big precursor that gets cleaved up into
many neuroactive peptides.20 And so that
of course caught my eye because I was
working on peptide hormone processing.
At the time, there weren’t that many
molecular biologists working in the ner-
vous system.
Then I started to think about what I
wanted to do. It was a choice, should I
stay in yeast? Because things were just
rocketing and there were so many unan-
swered questions. In the end I decided I
wanted to go into Neuroscience. But, I
needed to go to a lab where they were
doing some molecular biology and genet-
ics. So I went to visit Richard’s lab, and it
was like Alex Rich’s lab, it was this totally
chaotic place that was exciting and where
you can do what you want. There were
some people who had already started to
work on the nervous system. But everyone
was working on something completely
different.
Diana: How did you decide to work on
cloning serotonin receptors?
David: I think it was studying pep-
tide hormones in yeast and then think-
ing about mammalian equivalents in a
way—endorphins, enkephalins, a-MSH,
and wondering about how these things
are working in the brain. That got me
thinking about signaling in the brain.
And I didn’t stay with peptide hor-
mones but I went to monoamines,
because I was interested in things like
Figure 2. David McKemy (back, former postdoc; now Professor at University of Southern California),
Gunther Hollopeter (front, former graduate student; now postdoc, Jorgenson lab) with David Julius
(middle) picking cDNA library clones that were candidate cold receptors. One of these clones
encoded the cold and menthol receptor, TRPM8. 2001. Reproduced by permission of Sven E Jordt,
Duke University School of Medicine.
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natural products and hallucinogens. So
I think that’s where my interest in natu-
ral products came from.
I started reading some books by Sol
Snyder (Fig. 4). Sol’s always been kind of
an influence on me. He approached sci-
ence in such a different way than the peo-
ple I’ve worked for. He has a paradigm
that’s all his own and unique. And at the
time, as I read his work I realized he was
the person who identified some opiate
receptors using ligand binding assays and
had a whole other take on neuroscience
and molecular pharmacology that he really
revolutionized. That influenced me as
well, thinking about how Sol approached
science using natural products like mor-
phine to understand what their endoge-
nous targets were.
Diana: But you never worked with Sol?
David: I never worked with him. I’ve
talked to him on a number of occasions.
He’s influenced me a lot. He’s a really
interesting guy and really fun to talk to.
His discoveries are monumental. His
discovery of m-opioid receptor is one of
the great achievements in modern
neuropharmacology.21
Diana: Tell me about starting your
own lab (Fig. 5). What was the first thing
you did?
David: The first thing I did was clone
the 5-HT3 receptor.22 I planned to work
on all the GPCRs and reclone the first
couple of serotonin receptor subtypes. I
started thinking, “What’s the one quirky
member of this family?” There was all this
work on this 5-HT3 receptor that showed
there were binding sites in the brain and it
was this very mysterious thing. Was it
really a channel? What relationship does it
have to other serotonin receptors? What
does it do? A lot of people were looking
for this receptor, there were drug compa-
nies that were trying to affinity purify it
because there were such good drugs. And
so we expression cloned it. That was kind
of our first big hit, and that got me inter-
ested in channels and GPCRs, at least for
a while.
Diana: How did you begin working on
pain?
David: There was a sort of a small
fledgling effort in terms of people who
wanted to look at the molecular biology of
nociception. And the 5-HT3 receptor was
known to be expressed in a subset of sen-
sory neurons. And so I started getting
more and more interested in what these
cells were and what they do. I started read-
ing about pain and I thought this was kind
of an interesting area. Because I’d always
been a little frustrated, working on neuro-
transmitter receptors in the brain, it
seemed like such a distance between
behavior and molecular biology. And it
looked like in a sensory system you could
do that a little bit better. You could give
stimuli and ask what was happening. And
of all the sensory systems, pain was the
one that seemed to be the least picked
over. But of everybody who was at all
interested, and there weren’t very many in
molecular biology, they were all interested
in things like capsaicin. And I knew
enough to know that that was kind of a
holy grail. And I thought, maybe it’s one
of these other channels that we’ve
Figure 3. David Julius (right) and Diana Bautista (left, former postdoc; now Associate Professor at
University of California, Berkeley) cloning TRPA1 mutants. 2003. Reproduced by permission of Gun-
ther Hollopeter, PhD, University of Utah.
Figure 4. David Julius (left) with Sol Snyder (right, Professor at Johns Hopkins School of Medicine)
at an awards ceremony in 2014. Reproduced by permission of Michael J Caterina MD, PhD, Johns
Hopkins School of Medicine.
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identified, some P2X or 5-HT3 subtype
lurking in there. You have to remember
that genomics was just starting, so it
wasn’t so easy to go in and pull out genes.
People were pulling out different subtypes
of P2Xs at the time and 5HT receptors,
and it was hard work. And every time they
get one, they asked is it a capsaicin
receptor?
We tried that for a while, and then I
just decided, maybe we shouldn’t just
look where we’re shining the light, that we
have to step back. But there were a lot of
risks, obviously, nobody really knew. Up
until the time we cloned it, there were still
papers saying it wasn’t really a real recep-
tor. And one day I remember standing in
the supermarket looking at all these rows
of spices. Holly (Ingraham, professor at
UCSF and David’s spouse) was off some-
where, and she came around and I said,
“This is such an interesting problem.”
And she said, “So quit f**king around and
do it!” And then I decided, I just got to do
this! Mike (Caterina) was sniffing around
GABA receptors, but then I heard this
rumor that Benny Bentler had figured out
what GABAB receptors were. So I said
“You know what? We just oughta do this
capsaicin thing. You can take a risk work-
ing on something you’re going to get
scooped on. Or you could just try this.”
And so he was game for it.
Diana: Tell me about the cloning of
TRPV1.9
David: We originally tried using
oocytes to clone it, but decided it was too
laborious, we’ll never make enough RNA.
This thing was supposed to be some sort
of calcium channel, maybe. Whatever it
does, it increases calcium in cells. We had
this calcium imaging rig that I had
bought, because I went to see Rich Lewis
and tried to put together a little system. It
took us awhile because we didn’t know
what we were doing. We were getting peo-
ple from different labs to help us do differ-
ent things, learn how to culture neurons.
And then we just did it.
Diana: And so you saw calcium signals
in DRG neurons first?
David: Yeah
Diana: What year was this?
David: I think 1996. And then I said
you know, if we’re going to do this, since
we had never done expression cloning in
mammalian cells before with calcium sig-
nals, we have to mock this up. We had to
make a library. We had made libraries
before, but never from DRG (dorsal root
ganglia). Lucky for us, at the time, we had
help from Hey-Young (Kong) who was
post-doc with Moses Chao. She called me
up and said, “We want to make a library
from DRG from embryonic and adult
mouse. But we don’t know how to make
libraries so can we come to your lab and
do it?” And I said “Yeah, ok because we
want to make those libraries too.” Then
we just started screening, and, within a
couple of weeks, we had some positives.
I think it was fast. And I remember
going away for like 2 d to give a seminar
and then I came back and Mike had a
big grin on his face and said, “I got to
show you something!” So we went into
the imaging room and he got the com-
puter going and I could see there was
nothing and then all of a sudden
BOOM! Like four cells just went blazing
with capsaicin. Then within 3 or 4
weeks we had a single clone.
Then the question after we got it was
-what is this thing? What does it look like?
I had never really spent any time thinking
about TRP channels, at all. I mean,
nobody had, really.
Diana: Right, because there wasn’t very
much out there on these channels at the
time.
David: Nobody was really that inter-
ested in them. I remember that I wrote
in a book, “For more general perspec-
tive, the cloning of the vanilloid recep-
tor put a spotlight on TRP channels as
important new players in vertebrate
sensory systems. In retrospect this
should not have come as a great sur-
prise given the well established role of
TRP channels in fly phototransduction,
but for whatever reason, their relevance
to sensory signaling in higher systems
had not been fully appreciated.” And it
was true.
David: So we got this sequence.
Diana: And it was related to Drosoph-
ila TRP?
David: Well they had these ankyrin
repeats, and there’s no other channel that
had ankyrin repeats. And then Mike said
“You know I think they’re related to these
things called TRP channels!” “Great,
what’s that?” And so we started looking at
this. Then when we cloned it, the real
question was, what does this thing nor-
mally do? You know, in retrospect it seems
like Heat-capsaicin (go together), but no
one had ever really enunciated that.
Except to say that a lot of capsaicin-sensi-
tive cells were heat sensitive. This was the
legacy of Snyder in a way, that capsaicin
was an exogenous agent mimicking the
effects of an endogenous agent. Everyone
thought there would be an endogenous
capsicone. And you know, there’s truth in
that as well, with protons, anandamide,
other bioactive lipids, prostaglandins. But
these papers had come out from
McNaughton and Cesare recording heat-
activated currents,2 so you knew that there
must have been some sort of heat-acti-
vated conductance. But things hadn’t
gelled enough to really know what was
going on and the pharmacology wasn’t
good enough for people to put 2 and 2
together.
Figure 5. The current members of the Julius lab, UCSF 2015.
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Diana: Yeah and I looked at some of
the early current measurements too. And
there weren’t really good examples com-
paring the current triggered by capsaicin
and the current activated by heat.
David: Yes, and put them together.
There were some, Rang had sort of tiptoed
around that a bit. And it was known that
there were similar non-selective cation
channels. Sometimes heat-evoked currents
would be blocked by Ruthenium red and
sometimes not. Of course, there were a lot
of species differences and that complicated
things. Because some things were done in
rabbits and some in rats and mice, so
there’s a lot of species variation, which we
now know to be the case.
So from our perspective, we literally
just expressed the thing in oocytes and
started throwing things at it that caused
pain: bradykinin, serotonin and all this
stuff. And then one day we decided “Hey,
what about these physical stimuli? Like
pressure and heat?” So one day we just
heated up the chamber and all of a sudden
we saw these currents. I mean, it was really
exciting but it was also kind of worrying,
because we had no experience in doing
that kind of stuff. I just thought “Oh my
god, what if this is some major artifact
because we were changing the grounding
or something?” We had convinced our-
selves that, compared to background, we
could really see these heat-evoked cur-
rents. But I was always worried about it.
And we convinced ourselves it was real,
but we didn’t quite understand it yet.
Nobody had that much experience with
this. We thought we really had to put this
as a major part of the paper, because we
really think this is real and it made sense.
We did as many controls as we could
figure out. But (I thought) god, what if
it’s just some trivial thing? You put in this
protein, and somehow it makes the cells
heat sensitive. And so, I lost a lot of sleep
over it but we decided that we had been as
careful as we could reasonably be, and so
we just got to plant our flag on that. And
everybody else started looking at it, and
collectively we all got more sophisticated
at looking at heat-evoked currents.
Diana: Wow, that’s amazing. So were
you convinced that there was then going
to be a big phenotype in the TRPV1
knockout?
David: Oh well, we didn’t know,
because I think there are multiple ways to
sense heat. But it turned out there is a big
phenotype in the tail-flick assay.10 And I
don’t know why that is, but it could be
because the tail in the mouse is a thermo-
regulatory organ. It’s very highly inner-
vated by heat-sensitive fibers. What
looked less profound, but it was still pretty
robust, was the hot-plate test. And there
the expectation was that we would see dif-
ferences at a cooler threshold, closer to
43C but I think naively we were equating
the biophysical aspects of the channel with
the psychophysical.
Diana: You saw it at higher
temperatures.
David: Yeah, and we were scratching
our heads thinking, “What does this
mean?” And then we just thought that
“Well, if there’s any input to the (spinal)
cord, maybe that’s enough to discriminate
noxious from innocuous.” We sort of fig-
ured that might be the case.
The most dramatic phenotype that we
saw was looking at injury models where
TRPV1 was required for thermal hyper-
sensitivity. In addition, 2 observations
using TRPV1 antagonists really solidified
the role of this channel in acute thermo-
sensation. First, drugs in human clinical
trials decreased thermal acuity. Second,
early phase TRPV1 inhibitors, increased
body temperature by 0.6 to 2 degrees and
induced hyperthermia,23 suggesting that
the silencing of these peripheral receptors
causes the body to think it’s cold.
But it was only after the cloning and
characterization of TRPM8 that I felt that
TRP channels are bona fide heat sensors
and play key roles in peripheral somato-
sensation.11 The TRPM8 phenotype was
very dramatic. Like TRPV1, TRPM8
plays a key role in both acute temperature
sensation and thermal hypersensitivity.
Human studies using TRPM8 antagonists
showed the opposite results of drugs that
block TRPV1, namely hypothermia. And
of course we have yet to see how effective
drugs targeting these channels will be for
treating pain, itch or conditions like cold
allodynia.
Diana: Do you have words of advice
for a successful career in science?
David: You have to be open-minded
and objective and trust that you know
what good data and science is. You need
to be willing to be wrong, but don’t be
too quick to say you’re wrong. Trust your
data and construct a simple model. You
have to constantly ask your self: are my
findings advancing the field? Are people
using your tools? Are there any therapeutic
benefits?
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